Podoplanin: an emerging cancer biomarker and therapeutic target

Harini Krishnan, Julie Rayes, Tomoyuki Miyashita, Genichiro Ishii, Edward P. Retzbach, Stephanie A. Sheehan, Ai Takemoto, Yao Wen Chang, Kazue Yoneda, Jun Asai, Lasse Jensen, Lushun Chalise, Atsushi Natsume*, Gary S. Goldberg

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

52 Citations (Scopus)
107 Downloads (Pure)


Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR-T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.

Original languageEnglish
Pages (from-to)1292-1299
Number of pages8
JournalCancer Science
Issue number5
Early online date25 Mar 2018
Publication statusPublished - May 2018


  • c-type lectin-like receptor 2
  • cancer
  • chemotherapy
  • podoplanin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Podoplanin: an emerging cancer biomarker and therapeutic target'. Together they form a unique fingerprint.

Cite this